Rethinking the reasons to treat atrial fibrillation? the role of dronedarone in reducing cardiovascular hospitalizations

European Heart Journal

Volumn 30, Issue 20, 2009, Pages 2438-2440

  Falk, Rodney H ^a   Camm, A John ^b  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE;

CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HOSPITALIZATION; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SIDE EFFECT; SINUS RHYTHM; SYMPTOM; TREATMENT OUTCOME;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HOSPITALIZATION; HUMANS; RISK FACTORS;

EID: 76749171157     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp381     Document Type: Note

References (15)

1. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-1513.
2. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677.
3. Falk RH. Atrial fibrillation or sinus rhythm? Controversy and contradiction in quality of life outcomes. J Am Coll Cardiol 2006;48:731-733.
4. Steven D, Rostock T, Lutomsky B, Klemm H, Servatius H, Drewitz I, Friedrichs K, Ventura R, Meinertz T, Willems S. What is the real atrial fibrillation burden after catheter ablation of atrial fibrillation? A prospective rhythm analysis in pacemaker patients with continuous atrial monitoring. Eur Heart J 2008;29:1037-1042.
5. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillation after cardiover-sion: results of the PAFAC trial. Eur Heart J 2004;25:1385-1394.
6. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007;28:2803-2817.
7. McNamara RL, Brass LM, Drozda JP Jr, Go AS, Halperin JL, Kerr CR, Levy S, Malenka DJ, Mittal S, Pelosi F Jr., Rosenberg Y, Stryer D, Wyse DG, Radford MJ, Goff DC Jr., Grover FL, Heidenreich PA, Peterson ED, Redberg RF. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol 2004;44:475-495.
8. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678.
9. Wyse DG, Slee A, Epstein AE, Gersh BJ, Rocco JT, Vidaillet H, Volgman A, Weiss R, Shemanski L, Greene HL. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm 2004;1:531-537.
10. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007;41:599-605.
11. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527 e521-529.
12. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341: 857-865.
13. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 2001;104:292-296.
14. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687.
15. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-791.